Daily Medication Pearl: Benralizumab (Fasenra)

Benralizumab (Fasenra) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.

Medication Pearl of the Day: Benralizumab (Fasenra)

Indication: Benralizumabis an interleukin-5 receptor (IL-5Rα) alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older and with an eosinophilic phenotype.

Insight:

  • Dosing: Administer by subcutaneous injection. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter
  • Dosage form: Injection 30 mg/mL solution in a single-dose prefilled syringe. Injection 30 mg/mL solution in a single dose autoinjector Fasenra Pen.
  • Adverse events (AEs): Most common AEs are headache and pharyngitis.
  • Mechanism of action: Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the IL-5Rα with a dissociation constant of 11 pM.
  • Manufacturer: AstraZeneca

Sources: